In this article, we briefly review the pathophysiology and pertinent signals associated with food intake, the recently approved pharmacological treatments for obesity, and several novel treatments currently under investigation
Comprehensive Medical Screening: Clinicians should evaluate for: Thyroid nodules or goiter : Baseline neck examination and review of recent thyroid ultrasound if clinically indicated Personal or family history of thyroid cancer : Particularly medullary thyroid carcinoma Comorbid conditions : Type 2 diabetes, cardiovascular disease, pancreatitis history Gastrointestinal disorders : Severe gastroparesis (potential contraindication) Renal function : Use caution in patients at risk for volume depletion/renal impairment Psychiatric conditions : Depression, eating disorders Pregnancy status : These medications are not recommended during pregnancy and should be discontinued when pregnancy is recognized Laboratory Assessment: Baseline testing should include: TSH and free T4 Comprehensive metabolic panel (renal and hepatic function) Lipid panel Hemoglobin A1c (if diabetic or prediabetic) Routine calcitonin screening or thyroid ultrasound is not recommended solely for GLP-1 therapy initiation
Access to GLP-1s is only available to people with a BMI of 30 or higher, or 27 and higher with a weight-related health condition like high blood pressure, high cholesterol, or type 2 diabetes
Expertly formulated to help support GLP-1 levels naturally Helps promote digestive health for GLP-1 users Contains an advanced blend of 13 probiotic strains and 10 billion CFU One capsule daily promotes healthy digestion and supports regularity GLP-1 Support aids nutrient uptake and assimilation leading to potential health benefits Supplement Facts Serving Size: 1 Capsule Other Ingredients: Gelatin, microcrystalline cellulose, silica, magnesium stearate
However, rebound weight gain during a taper-off period is frustrating and avoidable
